Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Dr. Raje on the Potential Utility of Belantamab Mafodotin in Multiple Myeloma

April 24th 2020

Noopur Raje, MD, discusses the potential utility of belantamab mafodotin in multiple myeloma.

Dr. Shah on the Role of Venetoclax in Multiple Myeloma

April 23rd 2020

Nina Shah, MD, associate professor of medicine, Department of Medicine, at the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discusses the role of venetoclax (Venclexta) in multiple myeloma.

CAR T-Cell Therapy Continues Forward in Multiple Myeloma Development

April 23rd 2020

Nina Shah, MD, highlights some of the recent advances that have been made with CAR T-cell therapy in multiple myeloma, as well as other exciting updates in the space.

Dr. Friedman on the Future of Selinexor in Multiple Myeloma

April 22nd 2020

Robb S. Friedman, MD, discusses the future of selinexor in multiple myeloma.

Dr. Yee on Treatment Considerations in Relapsed/Refractory Multiple Myeloma

April 22nd 2020

Andrew Yee, MD, discusses treatment considerations in relapsed/refractory multiple myeloma.

Dr. Weitzman on Challenges of Treating Penta-Refractory Multiple Myeloma

April 21st 2020

James Weitzman, MD, discusses the challenges of treating patients with penta-refractory multiple myeloma.

RVd Induction Impresses in Myeloma, But 4-Drug Regimens Mark the Future

April 17th 2020

The 3-drug induction regimen of lenalidomide, bortezomib, and dexamethasone led to impressive overall survival outcomes and a very good partial response or better in nearly 90% of patients with newly diagnosed multiple myeloma.

Dr. Morgan on Idecabtagene Vicleucel in Multiple Myeloma

April 17th 2020

Gareth J. Morgan, MD, PhD, discusses research examining idecabtagene vicleucel in relapsed/refractory multiple myeloma.

Dr. Braunstein on Considerations for Stem Cell Transplant Eligibility in Myeloma

April 16th 2020

Marc J. Braunstein, MD, PhD, factors to consider when determining whether a patient with multiple myeloma is eligible for stem cell transplant.

Stem Cell Mobilization Strategies Call for Careful Consideration in Myeloma

April 15th 2020

Shaji Kumar, MD, discusses the role of stem cell transplant in multiple myeloma, different techniques for stem cell mobilization, and remaining challenges faced with this modality.

Dr. Davies on the Use of Carfilzomib in Multiple Myeloma

April 14th 2020

Faith E. Davies, MD, discusses the dosing of carfilzomib in the treatment of patients with multiple myeloma.

Dr. Morgan on the Role of Venetoclax in Multiple Myeloma

April 14th 2020

Gareth J. Morgan, MD, PhD, discusses the role of venetoclax in treating patients with multiple myeloma.

Dr. Davies on Promise of Venetoclax in Relapsed/Refractory Myeloma

April 13th 2020

Faith E. Davies, MD, discusses the use of venetoclax as a precision medicine approach in patients with relapsed/refractory multiple myeloma.

Controversy Surrounds Treatment of High-Risk Smoldering Myeloma

April 6th 2020

A cure concept has not yet been established for asymptomatic and untreated patients with high-risk smoldering myeloma, and debate needs to be initiated surrounding how these patients can be treated sustainably while also taking into account their age, comorbidities, fitness, personal preference, and adverse events of the therapeutic agents.

Dr. Friedman on the Mechanism of Action of Selinexor in Multiple Myeloma

April 4th 2020

Robb S. Friedman, MD, discusses the mechanism of action of selinexor in multiple myeloma.

Dr. Braunstein on Transplant Eligibility in Multiple Myeloma

April 3rd 2020

Marc J. Braunstein, MD, PhD, discusses transplant eligibility in multiple myeloma.

Charting New Territory in Multiple Myeloma Amid COVID-19 Crisis

March 31st 2020

Ajai Chari, MD, discusses the impact of the COVID-19 outbreak on hospital protocols and the measures that are being taken to reduce the spread of the virus.

Isatuximab Affords the R/R Multiple Myeloma Setting a Tolerable New Alternative

March 31st 2020

Ken Shain, MD, PhD, discusses isatuximab-irfc and its potential to move into different stages of the multiple myeloma paradigm following further clinical investigation.

FDA Approval Sought for Idecabtagene Vicleucel in Multiple Myeloma

March 31st 2020

A biologics license application has been submitted to the FDA for idecabtagene vicleucel (ide-cel; bb2121) for the treatment of adult patients with multiple myeloma who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody.

Dr. Munshi on Testing for MRD in Multiple Myeloma

March 21st 2020

Nikhil C. Munshi, MD, director of Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center, Kraft Family Chair, senior physician, Dana-Farber Cancer Institute, and professor of medicine, Harvard Medical School, discusses ways to test for minimal residual disease (MRD) in multiple myeloma.